Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125716521 | 12571652 | 1 | I | 20150727 | 20160719 | 20160719 | EXP | US-ACORDA-ACO_115038_2015 | ACORDA | 0.00 | F | Y | 63.49000 | KG | 20160719 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125716521 | 12571652 | 1 | PS | AMPYRA | DALFAMPRIDINE | 1 | Oral | 10 MG, BID | 22250 | 10 | MG | TABLET | BID | ||||||
| 125716521 | 12571652 | 2 | SS | AMPYRA | DALFAMPRIDINE | 1 | Oral | 10 MG, BID | 22250 | 10 | MG | TABLET | BID | ||||||
| 125716521 | 12571652 | 3 | SS | AMPYRA | DALFAMPRIDINE | 1 | Oral | 10 MG, BID | 22250 | 10 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125716521 | 12571652 | 1 | Gait disturbance |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125716521 | 12571652 | OT |
| 125716521 | 12571652 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125716521 | 12571652 | Abasia | |
| 125716521 | 12571652 | Blood glucose increased | |
| 125716521 | 12571652 | Blood pressure decreased | |
| 125716521 | 12571652 | Decreased appetite | |
| 125716521 | 12571652 | Therapy cessation | |
| 125716521 | 12571652 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |